Conduit Pharmaceuticals Inc
NASDAQ:CDT
Operating Margin
Conduit Pharmaceuticals Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
C
|
Conduit Pharmaceuticals Inc
NASDAQ:CDT
|
5.1m USD | N/A | |
UK |
E
|
Eight Capital Partners PLC
F:ECS
|
633.6T EUR | N/A | |
US |
G
|
GE Vernova LLC
NYSE:GEV
|
156.8B USD |
3%
|
|
US |
C
|
China Industrial Group Inc
OTC:CIND
|
100.5B USD |
10%
|
|
IN |
S
|
SAB Industries Ltd
BSE:539112
|
2.4B INR |
11%
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
83.3B Zac |
62%
|
|
US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
60B USD |
10%
|
|
US |
![]() |
Coupang Inc
F:788
|
48.1B EUR |
2%
|
|
US |
C
|
Circle Internet Group Inc
NYSE:CRCL
|
49.8B USD |
10%
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
30.2B CHF |
15%
|
|
ID |
![]() |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
582T IDR |
41%
|
Conduit Pharmaceuticals Inc
Glance View
Conduit Pharmaceuticals Inc is a US-based company operating in industry. The company is headquartered in San Diego, California. The company went IPO on 2022-02-03. Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The firm is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. The company is used as a treatment option for Hashimoto’s Thyroiditis (HT) and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Conduit Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 0%.